Patent awarded for latanoprost

ViSci has received a patent from the U.S. Patent and Trademark Office covering its proprietary formulation of latanoprost, which is contained in its controlled-release insert for the treatment of glaucoma.

The patent, which will be in effect at least until April 2030, is intended to protect, among other things, the chemical structure of the active ingredient in the company’s product. It covers the release of the active ingredient from the Eye-D subconjunctival insert and its use in treating elevated intraocular pressure in patients with glaucoma and ocular hypertension.

Recently ViSci successfully completed an ocular toxicology and safety study in animals and has filed an Investigational New Drug (IND) with the U.S. Food and Drug Administration to conduct a Phase 1/2a clinical study of its Eye-D Latanoprost controlled-release insert for the treatment of glaucoma. The study will be conducted at up to seven sites in the United States.

“We believe that our Eye-D controlled-release insert will provide an effective solution to the well-known poor compliance with chronic eye-drop administration commonly used today as a treatment for glaucoma,” said Suzana Nahum-Zilberberg, BioLight’s CEO. “This U.S. patent approval will strengthen our business, marketing and competitive advantages of our company.”